Skip to Content
MilliporeSigma

L5918

Lomustine

≥98%

Synonym(s):

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

Slide 1 of 2
Sign In to View Organizational & Contract Pricing

Select a Size

L5918-100MG

$160.65

$160.65

List Price$189.00Save 15%
Check Cart for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C9H16ClN3O2
CAS Number:
13010-47-4
Molecular Weight:
233.70
EC Number:
235-859-2
MDL number:
MFCD00012392
UNSPSC Code:
12352100
PubChem Substance ID:
329817632
NACRES:
NA.25

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98%

storage temp.

−20°C

SMILES string

ClCCN(N=O)C(=O)NC1CCCCC1

InChI

1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

InChI key

GQYIWUVLTXOXAJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR3029S4026L0745000
Lomustine ≥98%

Sigma-Aldrich

L5918

Lomustine

Lomustine pharmaceutical secondary standard, certified reference material

Supelco

PHR3029

Lomustine

Semustine

Sigma-Aldrich

S4026

Semustine

Lomustine European Pharmacopoeia (EP) Reference Standard

L0745000

Lomustine

assay

≥98%

assay

-

assay

-

assay

-

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

Quality Level

100

Quality Level

300

Quality Level

-

Quality Level

-

Biochem/physiol Actions

Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H301,H350

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCZ2627
MKCV3653
MKCS6368
MKCL2081
MKCJ4400

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Joann L Ater et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2641-2647 (2012-06-06)
PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
Carsten Friedrich et al.
European journal of cancer (Oxford, England : 1990), 49(4), 893-903 (2012-11-28)
Medulloblastoma in adulthood is rare. Knowledge is limited, and the efficacy and toxicity of chemotherapy--especially in nonmetastatic disease--is still elusive. Seventy adults aged ≥21 years (median age: 28.5 years) with nonmetastatic medulloblastoma were followed as observational patients within the prospective
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Moritz Stuplich et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), e180-e183 (2012-06-13)
Roger J Packer et al.
Neuro-oncology, 15(1), 97-103 (2012-10-27)
The purpose of the trial was to determine the survival and incidence of secondary tumors in children with medulloblastoma receiving radiotherapy plus chemotherapy. Three hundred seventy-nine eligible patients with nondisseminated medulloblastoma between the ages of 3 and 21 years were
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service